Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Sickle Cell Anemia (SCA), also called the Sickle Cell Disease (SCD), is an inherited hematological disorder characterized by a syndrome of acute anemia and a painful crisis.

The sickling hemoglobin, Hgb-S causes viscosity and inflammation of blood vessels.

Eventually, the red blood cells get eliminated from the circulation process, which leads to hemolytic anemia.

Who Took Part

The abstract describes 165 patients taking part.

165 patients participated in this randomized, double-blind, standard therapy-controlled, parallel-design trial.

The baseline time point was defined as the time spot before starting to deliver the experimental medication to the patients (month zero).

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Lactate dehydrogenase, high-density lipoprotein (HDL), low-density lipoprotein (LDL), hematocrit, reticulocyte count, and white-blood-cell count were determined at baseline (month zero) and end of the 10th month.

The pain severity was measured using the visual analog scale method (VAS).

At that time, the biodata of the patient on the frequency of pain episodes and the rest of the variables were collected, and the baseline data were one-year retrospective data.

What Was Measured

PubMed files the paper under topics including Anemia, Sickle Cell, Fatty Acids, Omega-3, Hydroxyurea, Pain, Vitamin D and Vitamins.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 165 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (European review for medical and pharmacological sciences), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.